Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-03-02 Sale |
2023-03-06 6:46 pm |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,074 | $3.627 | $18,403 | 290,794 (Direct) |
View |
| 2022-11-16 Sale |
2022-11-18 8:13 pm |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
4,342 | $4.4903 | $19,497 | 154,540 (Direct) |
View |
| 2022-08-16 Sale |
2022-08-18 6:21 pm |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
4,124 | $5.034 | $20,760 | 158,882 (Direct) |
View |
| 2022-05-17 Sale |
2022-05-19 5:08 pm |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
3,873 | $5.318 | $20,597 | 163,006 (Direct) |
View |
| 2022-03-01 Sale |
2022-03-03 7:02 pm |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
2,221 | $9.856 | $21,890 | 314,452 (Direct) |
View |
| 2022-02-10 Sale |
2022-02-14 5:42 pm |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,000 | $16 | $80,000 | 348,094 (Direct) |
View |
| 2022-01-03 Sale |
2022-01-05 4:47 pm |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,000 | $16.01 | $80,050 | 353,094 (Direct) |
View |
| 2021-12-01 Sale |
2021-12-03 4:15 pm |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,000 | $17.94 | $89,689 | 358,094 (Direct) |
View |
| 2021-11-16 Sale |
2021-11-18 5:52 pm |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
2,199 | $17.12 | $37,640 | 90,594 (Direct) |
View |
| 2021-11-02 Sale |
2021-11-04 4:10 pm |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,000 | $16.41 | $82,050 | 365,293 (Direct) |
View |
| 2021-08-17 Sale |
2021-08-19 7:32 pm |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
2,152 | $12.53 | $26,969 | 92,793 (Direct) |
View |
| 2021-05-18 Sale |
2021-05-20 4:32 pm |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,184 | $14.55 | $75,427 | 94,945 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-03-31 Option Award |
2025-04-02 09:00 am |
N/A 2035-03-31 |
Pyxis Oncology Inc. | PYXS | Dupont Jakob Director |
36,979 | $0.98 | 36,979 (Direct) |
View |
| 2024-09-03 Option Award |
2024-09-06 12:19 pm |
N/A 2034-09-02 |
Bolt Biotherapeutics Inc. | BOLT | Dupont Jakob Director |
66,984 | $0 | 66,984 (Direct) |
View |
| 2024-03-26 Option Award |
2024-03-28 4:32 pm |
N/A N/A |
Pyxis Oncology Inc. | PYXS | Dupont Jakob Director |
38,741 | $0 | 38,741 (Direct) |
View |
| 2023-09-22 Option Award |
2023-09-26 7:04 pm |
N/A 2033-09-22 |
Pyxis Oncology Inc. | PYXS | Dupont Jakob Director |
392,461 | $0 | 392,461 (Direct) |
View |
| 2023-08-23 Option Award |
2023-08-25 5:30 pm |
N/A 2030-09-01 |
Pyxis Oncology Inc. | PYXS | Dupont Jakob Director |
26,663 | $0 | 26,663 (Direct) |
View |
Ownership(A) |
2023-08-24 6:49 pm |
N/A 2031-02-12 |
Apexigen Inc. | APGN | Dupont Jakob Director |
0 | $0 | 20,489 (Direct) |
View |
| 2023-03-01 Option Award |
2023-03-03 5:15 pm |
N/A 2033-02-28 |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
459,315 | $0 | 613,855 (Direct) |
View |
| 2022-09-29 Option Award |
2022-10-03 6:12 pm |
N/A 2032-09-29 |
Apexigen Inc. | APGN | Dupont Jakob Director |
100,000 | $0 | 100,000 (Direct) |
View |
Ownership |
2022-08-08 5:09 pm |
N/A 2030-09-01 |
Apexigen Inc. | APGN | Dupont Jakob Director |
0 | $0 | 34,084 (Direct) |
View |
| 2022-03-01 Option Award |
2022-03-03 7:02 pm |
N/A 2032-02-28 |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
226,079 | $0 | 314,452 (Direct) |
View |
| 2022-02-10 Exercise |
2022-02-14 5:42 pm |
N/A N/A |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,000 | $9.58 | 348,094 (Direct) |
View |
| 2022-02-10 Exercise |
2022-02-14 5:42 pm |
N/A 2030-05-13 |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,000 | $0 | 348,094 (Direct) |
View |
| 2022-01-03 Exercise |
2022-01-05 4:47 pm |
N/A N/A |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,000 | $9.58 | 353,094 (Direct) |
View |
| 2022-01-03 Exercise |
2022-01-05 4:47 pm |
N/A 2030-05-13 |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,000 | $0 | 353,094 (Direct) |
View |
| 2021-12-01 Exercise |
2021-12-03 4:15 pm |
N/A N/A |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,000 | $9.58 | 358,094 (Direct) |
View |
| 2021-12-01 Exercise |
2021-12-03 4:15 pm |
N/A 2030-05-13 |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,000 | $0 | 358,094 (Direct) |
View |
| 2021-11-02 Exercise |
2021-11-04 4:10 pm |
N/A N/A |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,000 | $9.58 | 365,293 (Direct) |
View |
| 2021-11-02 Exercise |
2021-11-04 4:10 pm |
N/A 2030-05-13 |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
5,000 | $0 | 365,293 (Direct) |
View |
| 2021-03-01 Option Award |
2021-03-03 5:17 pm |
N/A 2031-02-28 |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
135,206 | $0 | 181,456 (Direct) |
View |
| 2020-05-14 Option Award |
2020-05-19 7:17 pm |
N/A 2030-05-13 |
Atara Biotherapeutics Inc. | ATRA | Dupont Jakob EVP, Head of R&D |
323,750 | $0 | 323,750 (Direct) |
View |